Matthew Foehr
Vorstandsvorsitzender bei OMNIAB, INC.
Vermögen: 22 Mio $ am 31.05.2024
Profil
Matthew William Foehr is currently the President, Chief Executive Officer & Director at OmniAb Operations, Inc. and OmniAb, Inc. He is also a Director at Ligand UK Research Ltd.
and Pelican Inc. In the past, he served as a Director at Ligand UK Group Ltd.
and as an Independent Director at Viking Therapeutics, Inc. Foehr's former positions include being an Independent Director at Ritter Pharmaceuticals, Inc., a Director at Ligand UK Ltd., and the President & Chief Operating Officer at Ligand Pharmaceuticals, Inc. He also held senior positions at Connetics Corp., Stiefel Laboratories, Inc., and GlaxoSmithKline LLC.
Foehr completed his undergraduate degree at Santa Clara University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
OMNIAB, INC.
3,01% | 24.05.2024 | 3 536 665 ( 3,01% ) | 15 Mio $ | 31.05.2024 |
| 15.03.2024 | 111 250 ( 0,10% ) | 7 Mio $ | 31.05.2024 |
Aktive Positionen von Matthew Foehr
| Unternehmen | Position | Beginn |
|---|---|---|
| VIKING THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.05.2014 |
| PFENEX INC. | Direktor/Vorstandsmitglied | 01.10.2020 |
| OMNIAB, INC. | Vorstandsvorsitzender | 01.11.2022 |
Ligand UK Group Ltd.
 Ligand UK Group Ltd. Financial ConglomeratesFinance Founded in 1995, Ligand UK Group Ltd. is a subsidiary of Ligand Pharmaceuticals, Inc. and functions as an investment holding company. The company is based in Cambridge, UK. | Direktor/Vorstandsmitglied | 12.10.2018 |
OmniAb Operations, Inc.
 OmniAb Operations, Inc. BiotechnologyHealth Technology OmniAb Operations, Inc. operates as a drug discovery company. It provides pharmaceutical industry partners access to antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform includes the Biological Intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse, that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company is headquartered in Emeryville, CA. | Vorstandsvorsitzender | 01.11.2022 |
Ligand UK Research Ltd.
 Ligand UK Research Ltd. Pharmaceuticals: MajorHealth Technology Part of Ligand Pharmaceuticals, Inc., Ligand UK Research Ltd. develops pharmaceutical products. The company is based in London, UK. Founded in 1995. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Matthew Foehr
| Unternehmen | Position | Ende |
|---|---|---|
| VERNALIS | Direktor/Vorstandsmitglied | 01.11.2022 |
| LIGAND PHARMACEUTICALS INCORPORATED | Präsident | 01.01.2022 |
| QUALIGEN THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.05.2020 |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Matthew Foehr
| Santa Clara University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
| VIKING THERAPEUTICS, INC. | Health Technology |
| OMNIAB, INC. | Commercial Services |
| Private Unternehmen | 9 |
|---|---|
Connetics Corp.
 Connetics Corp. BiotechnologyHealth Technology Connetics Corp. develops and commercializes dermatology products. The firm offers remedies for psoriasis in adults, eczema, seborrheic dermatitis, and acne. The company was founded in 1993 and is headquartered in Palo Alto, CA. | Health Technology |
Ritter Pharmaceuticals, Inc.
 Ritter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat digestive disorders and gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA. | Health Technology |
Stiefel Laboratories, Inc.
 Stiefel Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Stiefel Laboratories, Inc. engages in the manufacture of pharmaceutical products. It offers prescription and non-prescription dermatological and skin care products. The firm research, innovate and develop skin care treatments to health care professionals, patients and consumers. The company was founded in 1847 and is headquartered in Research Triangle Park, NC. | Health Technology |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Health Technology |
Ligand UK Ltd.
 Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
Ligand UK Group Ltd.
Ligand UK Group Ltd. Financial ConglomeratesFinance Founded in 1995, Ligand UK Group Ltd. is a subsidiary of Ligand Pharmaceuticals, Inc. and functions as an investment holding company. The company is based in Cambridge, UK. | Finance |
Pelican Inc
 Pelican Inc BiotechnologyHealth Technology Pfenex, Inc. is a development and licensing Biotechnology Company, which focuses on leveraging its Pfenex Expression Technology platform for developing and improving protein therapies. Its products include PF708, PF743, PF745, CRM197, PF810, PF753 and PFXX. The company was founded on November 19, 2009 and is headquartered in San Diego, CA. | Health Technology |
OmniAb Operations, Inc.
OmniAb Operations, Inc. BiotechnologyHealth Technology OmniAb Operations, Inc. operates as a drug discovery company. It provides pharmaceutical industry partners access to antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform includes the Biological Intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse, that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company is headquartered in Emeryville, CA. | Health Technology |
Ligand UK Research Ltd.
Ligand UK Research Ltd. Pharmaceuticals: MajorHealth Technology Part of Ligand Pharmaceuticals, Inc., Ligand UK Research Ltd. develops pharmaceutical products. The company is based in London, UK. Founded in 1995. | Health Technology |
